<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010512</url>
  </required_header>
  <id_info>
    <org_study_id>CLU484-P002</org_study_id>
    <nct_id>NCT05010512</nct_id>
  </id_info>
  <brief_title>Clinical Performance of Two Commercial, Daily Disposable Contact Lenses</brief_title>
  <official_title>Clinical Performance of Two Commercial, Daily Disposable Contact Lenses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the clinical performance of DAILIES TOTAL1 ( DT1)&#xD;
      contact lenses with Infuse contact lenses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will wear two products and be expected to attend 3 office visits. The individual&#xD;
      duration of participation will be approximately 3 weeks, which includes 16 to 22 days of lens&#xD;
      wear.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 31, 2021</start_date>
  <completion_date type="Actual">October 12, 2021</completion_date>
  <primary_completion_date type="Actual">October 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distance VA (logMAR) with study lenses</measure>
    <time_frame>Day 8 (-0/+3), each product</time_frame>
    <description>Visual acuity will be assessed with letter charts</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Refractive Errors</condition>
  <arm_group>
    <arm_group_label>DT1, then Infuse</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Delefilcon A contact lenses worn first, followed by kalifilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infuse, then DT1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Kalifilcon A contact lenses worn first, followed by delefilcon A contact lenses, as randomized. Each product will be worn bilaterally (in both eyes) for 8 (-0/+3) days on a daily wear, daily disposable basis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Delefilcon A contact lenses</intervention_name>
    <description>Commercially available silicone hydrogel contact lenses used as indicated</description>
    <arm_group_label>DT1, then Infuse</arm_group_label>
    <arm_group_label>Infuse, then DT1</arm_group_label>
    <other_name>DAILIES TOTAL1®</other_name>
    <other_name>DT1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Kalifilcon A contact lenses</intervention_name>
    <description>Commercially available silicone hydrogel contact lenses used as indicated</description>
    <arm_group_label>DT1, then Infuse</arm_group_label>
    <arm_group_label>Infuse, then DT1</arm_group_label>
    <other_name>Bausch + Lomb INFUSE™</other_name>
    <other_name>Infuse</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Habitually wears soft contact lenses in both eyes at least 5 days per week and at&#xD;
             least 10 hours per day;&#xD;
&#xD;
          -  At least 3 months of contact lens wearing experience;&#xD;
&#xD;
          -  Less than or equal to 0.75 diopter (D) astigmatism in each eye;&#xD;
&#xD;
          -  Best Corrected Visual Acuity (BCVA) better than or equal to 20/25 in each eye.&#xD;
&#xD;
          -  Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Current/previous DAILIES TOTAL1 and/or Infuse habitual lens wearer;&#xD;
&#xD;
          -  Monovision and/or multifocal lens wearer;&#xD;
&#xD;
          -  Routinely sleeps in habitual contact lenses;&#xD;
&#xD;
          -  Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Lead, Vision Care</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Investigator 6355</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6418</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 3950</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6614</name>
      <address>
        <city>Franklin Park</city>
        <state>Illinois</state>
        <zip>60131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6583</name>
      <address>
        <city>Eden Prairie</city>
        <state>Minnesota</state>
        <zip>55344</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 3382</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 6353</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alcon Investigator 2786</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 11, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contact lenses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

